Jean M. Bidlack

Prof. Jean M. Bidlack

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2000 in Clinical and Diagnostic Laboratory Immunology
Verified
Journal Article
Closed access
PDF file
JBJean M. Bidlack
Jean M. Bidlack

19 November 2008 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
JMJennifer L. Mathews
Jennifer L. Mathews
ASAlan V. Smrcka
Alan V. Smrcka
JBJean M. Bidlack
Jean M. Bidlack
The Gβγ subunit has been implicated in many downstream signaling events associated with opioids. We previously demonstrated that a small molecule inhibitor of Gβγ-subunit-dependent phospholipase (PLC) activation potentiated morphine-induced analgesia (Bonacci et al., 2006). Here, we demonstrate that this inhibitor, M119 (cyclohexanecarboxylic acid [2-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)-(9Cl)]), is selective for μ-opioid receptor-dependent analgesia and has additional efficacy in mouse models of acute tolerance and dependence. When administered by an intracerebroventricular injection in mice, M119 caused 10-fold and sevenfold increases in the potencies of morphine and the μ-selective peptide, DAMGO, respectively. M119 had little or no effect on analgesia induced by the κ agonist U50,488 or δ agonists DPDPE or Deltorphin II. Similar results were obtainedin vitro, as only activation of the μ-opioid receptor stimulated PLC activation, whereas no effect was seen with the κ- and δ-opioid receptors. M119 inhibited μ-receptor-dependent PLC activation. In studies to further explore thein vivoefficacy of M119, systemic administration M119 also resulted in a fourfold shift increase in potency of systemically administered morphine. Of particular interest, M119 was also able to attenuate acute, antinociceptive tolerance and dependence in mice treated concomitantly with both M119 and morphine. These studies suggest that small organic molecules, such as M119, that specifically regulate Gβγ subunit signaling may have important therapeutic applications in enhancing opioid analgesia, while attenuating the development of tolerance and dependence.

8 July 2006 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
JBJean M. Bidlack
Jean M. Bidlack
MKMaxim Khimich
Maxim Khimich
APAmy L. Parkhill
Amy L. Parkhill
SSSarah Sumagin
Sarah Sumagin
BSBaoyong Sun
Baoyong Sun
CTChristopher M. Tipton
Christopher M. Tipton

1 November 2018 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
JBJean M. Bidlack
Jean M. Bidlack
BKBrian I. Knapp
Brian I. Knapp
DDDaniel R. Deaver
Daniel R. Deaver
MPMargarita Plotnikava
Margarita Plotnikava
DADerrick Arnelle
Derrick Arnelle
MNMark N. Namchuk
Mark N. Namchuk
A combination of buprenorphine (BUP) and samidorphan (SAM) at a 1:1 fixed dose ratio (mg/mg), is being investigated as an adjunctive treatment for major depressive disorder (BUP/SAM, ALKS 5461). Both [3H]BUP and [3H]SAM bound to the mu, kappa and delta opioid receptors (MOR, KOR and DOR, respectively) with Kd values of 3 nM or less. [3H]BUP dissociated slower from the MOR than [3H]SAM did. In the [35S]GTPγS assay, BUP was a partial agonist at the MOR, KOR and DOR. SAM was an antagonist at the MOR and a partial agonist at the KOR and DOR. The pharmacology of the combination of SAM and BUP was characterized at ratios similar to the molar ratios of both compounds at steady state in humans. In all assessments, SAM reduced the efficacy of BUP at the MOR without altering its potency. At the KOR, SAM had no significant effect on the activity of BUP. In bioluminescent resonance energy transfer assays, SAM, naltrexone, and naloxone were partial agonists when the MOR was coupled to the GαoB and Gαz, and were antagonists when coupled to Gαi. At the KOR, SAM was a partial agonist activating GαoA and GαoB and a full agonist in stimulating Gαz. SAM inhibited BUP9s recruitment of β-arrestin to the MOR, suggesting an attenuation of BUP9s efficacy in activating G proteins correlated with an inhibition of β-arrestin recruitment. The collective data suggest that SAM attenuates the efficacy of BUP under all conditions tested at the MOR and DOR, but had little effect on BUP activity at the KOR.

1 July 2002 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
JBJean M. Bidlack
Jean M. Bidlack
DCDana J. Cohen
Dana J. Cohen
JMJay P. McLaughlin
Jay P. McLaughlin
RLRongliang Lou
Rongliang Lou
YYYingchun Ye
Yingchun Ye
MWMark P. Wentland
Mark P. Wentland
To obtain benzomorphans with a longer duration of action that may be potential therapeutics for treating cocaine abuse, 8-carboxamidocyclazocine was synthesized. The pharmacological properties of 8-carboxamidocyclazocine were compared with the parent compound cyclazocine. Changing the 8-hydroxyl group on cyclazocine to an 8-carboxamido group resulted in only a 2-fold decrease in the affinity of the compound for the κ-receptor, and no change in the affinity for the μ-opioid receptor, with both compounds havingKi values of less than 1 nM, based on radioligand binding assays. In the guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding assay, the two compounds produced moderate stimulation of GTP binding to the human κ- and μ-receptors. When given by i.c.v. injection, the compounds produced less than 60% antinociception in the mouse 55°C warm-water tail-flick test. However, in the mouse writhing test, the compounds had high potency in producing antinociception. Antinociception induced by either 8-carboxamidocyclazocine or cyclazocine was mediated by both κ- and μ-opioid receptors. Cyclazocine acted as a μ-antagonist in addition to its agonist properties at the μ-receptor, as measured by the inhibition of morphine-induced antinociception. In contrast, 8-carboxamidocyclazocine did not inhibit morphine-induced antinociception, demonstrating that it was not a μ-opioid receptor antagonist in this assay. An i.p. injection of an ED70 dose of 8-carboxamidocyclazocine produced antinociception that lasted for 15 h in contrast to cyclazocine, which produced antinociception, lasting 2 h. 8-Carboxamidocyclazocine is a novel, long-acting benzomorphan, which possesses pharmacological properties that are distinct from the properties of cyclazocine.